Ann: December 2023 Preclinical & Clinical Program Update, page-9

@Davisite are you able to expand a bit on how these AML mouse models could typically be expected to translate into human application?

For example, in the first graph (MOLM-13-luc), median survival went from 18 days (vehicle) to 30 days for the Bisantrene+Decitabine combination, with the single agents falling somewhere in between. Are these models far more aggressive in causing death in mice than in humans?

For the Bis+Dec combination to be a "major winner", what sort of effect would we be looking to see in human testing? I'm assuming it would be more than a 12 day increase in median survival as was seen in the mouse model.

Thanks in advance.